Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Tarextumab |
Synonyms | |
Therapy Description |
Tarextumab (OMP-59R5) is a monoclonal antibody that binds Notch2 and Notch3 to prevent ligand interaction, which may inhibit angiogenesis and tumor growth (PMID: 25934888, PMID: 30591982). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Tarextumab | OMP-59R5|OMP-59R5 | NOTCH2 Antibody 3 NOTCH3 Antibody 2 | Tarextumab (OMP-59R5) is a monoclonal antibody that binds Notch2 and Notch3 to prevent ligand interaction, which may inhibit angiogenesis and tumor growth (PMID: 25934888, PMID: 30591982). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01647828 | Phase Ib/II | Nab-paclitaxel Gemcitabine Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer | Completed | USA | 0 |
NCT01859741 | Phase Ib/II | Cisplatin Etoposide Carboplatin Tarextumab | A Phase 1b/2 Study of OMP-59R5 in Combination With Etoposide and Platinum Therapy in Subjects With Untreated Extensive Stage Small Cell Lung Cancer (PINNACLE) | Terminated | USA | 0 |